Evidence map›Paper›PMID 40530383›Full record

ReviewIJTLD open2025

Clinical best practices for caring for people with expanded resistance to newer TB drugs.

T Nkomo, Z Udwadia, D Vambe, A van Rie, S S Thi, J Stillo, A Stambekova, A Sinha, M L Rich, A Reuter and 17 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

T NkomoNational Tuberculosis Control Program, Manzini, Eswatini.
Z UdwadiaHinduja Hospital and Research Center, Mumbai, India.
D VambeBaylor College of Medicine, Mbabane, Eswatini.
A van RieUniversity of Antwerp, Antwerp, Belgium and Stellenbosch University, Stellenbosch, South Africa.
S S ThiUSAID, Mbabane, Eswatini.
J StilloWayne State University, Detroit, MI, USA.
A StambekovaPartners In Health, (Almaty, Kazakhstan and Boston, MA, USA).
A SinhaMédecins Sans Frontières.
M L RichPartners In Health, (Almaty, Kazakhstan and Boston, MA, USA).
A ReuterUniversity of Antwerp, Antwerp, Belgium and Stellenbosch University, Stellenbosch, South Africa.
J PatelHinduja Hospital and Research Center, Mumbai, India.
R Otto-KnappGerman Central Committee to Combat Tuberculosis, Berlin, Germany.
I MottaMédecins Sans Frontières.
A MesicMédecins Sans Frontières.
L McKennaTreatment Action Group, New York, NY, USA.
S MaruNew York City Department of Health, New York, NY, USA.
E LessemCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA;.
C LangeClinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
N KiriaNational Center for Tuberculosis and Lung Disease, Tbilisi, Georgia.
Y KherabiInfectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
G GüntherDepartment of Pulmonology, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, Bern, Switzerland.
L GuglielmettiMédecins Sans Frontières.
T DecrooGerman Central Committee to Combat Tuberculosis, Berlin, Germany.
L ChenUniversity of California, San Francisco, San Francisco, CA, USA.
A AsheshSurvivors Against TB, New Delhi, India.
A AbubakirovPartners In Health, (Almaty, Kazakhstan and Boston, MA, USA).
J FurinHarvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStrains of

methodsIn the absence of trial data on how to care for these individuals, a group of clinical, programmatic and civil society experts came together to generate a series of best clinical practices. These practices are based on the published literature and on experience caring for individuals with these forms of TB.

resultsWe discuss best clinical practices in the following areas: 1) drug susceptibility testing; 2) regimen design; 3) adverse event monitoring and management; 4) special populations; 5) shared decision making and informed consent; 6) holistic packages of support; and 7) pre-approval access/compassionate use of newer TB compounds.

conclusionWhile we await systematic studies of treatment approaches to generate the necessary evidence base, the clinical practices described here can be used to guide the programmatic care of people with strains of

Indexed as

holistic supportresistancetreatment regimentuberculosis

Identifiers

PMID40530383
PMCPMC12168730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.